These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12924588)

  • 1. Quantitative structure-activity relationships for predicting metabolism and modeling cytochrome p450 enzyme activities.
    Long A; Walker JD
    Environ Toxicol Chem; 2003 Aug; 22(8):1894-9. PubMed ID: 12924588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing rates and clearance in P450-mediated reactions: QSARs for substrates of the xenobiotic-metabolizing hepatic microsomal P450s.
    Lewis DF; Dickins M
    Toxicology; 2002 Jan; 170(1-2):45-53. PubMed ID: 11750082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms.
    Kirchmair J; Williamson MJ; Tyzack JD; Tan L; Bond PJ; Bender A; Glen RC
    J Chem Inf Model; 2012 Mar; 52(3):617-48. PubMed ID: 22339582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P450 structures and oxidative metabolism of xenobiotics.
    Lewis DF
    Pharmacogenomics; 2003 Jul; 4(4):387-95. PubMed ID: 12831319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary effects on cytochromes P450, xenobiotic metabolism, and toxicity.
    Yang CS; Brady JF; Hong JY
    FASEB J; 1992 Jan; 6(2):737-44. PubMed ID: 1537464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative structure-activity relationships (QSARs) for inhibitors and substrates of CYP2B enzymes: importance of compound lipophilicity in explanation of potency differences.
    Lewis DF; Ito Y; Lake BG
    J Enzyme Inhib Med Chem; 2010 Oct; 25(5):679-84. PubMed ID: 20100069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach.
    Korolev D; Balakin KV; Nikolsky Y; Kirillov E; Ivanenkov YA; Savchuk NP; Ivashchenko AA; Nikolskaya T
    J Med Chem; 2003 Aug; 46(17):3631-43. PubMed ID: 12904067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coumarins and P450s, Studies Reported to-Date.
    Foroozesh M; Sridhar J; Goyal N; Liu J
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31022888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxygen and xenobiotic reductase activities of cytochrome P450.
    Goeptar AR; Scheerens H; Vermeulen NP
    Crit Rev Toxicol; 1995; 25(1):25-65. PubMed ID: 7734059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of human cytochrome P-450 enzymes in the metabolism of xenobiotics].
    Monostory K; Vereczkey L
    Acta Pharm Hung; 1995 Sep; 65(5):147-56. PubMed ID: 7484161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles.
    Lewis DF
    Toxicology; 2000 Apr; 144(1-3):197-203. PubMed ID: 10781888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative structure-activity relationships (QSARs) in inhibitors of various cytochromes P450: the importance of compound lipophilicity.
    Lewis DF; Lake BG; Dickins M
    J Enzyme Inhib Med Chem; 2007 Feb; 22(1):1-6. PubMed ID: 17373540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards Predicting the Cytochrome P450 Modulation: From QSAR to Proteochemometric Modeling.
    Shoombuatong W; Prathipati P; Prachayasittikul V; Schaduangrat N; Malik AA; Pratiwi R; Wanwimolruk S; Wikberg JES; Gleeson MP; Spjuth O; Nantasenamat C
    Curr Drug Metab; 2017 Jul; 18(6):540-555. PubMed ID: 28322159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational models for predicting interactions with cytochrome p450 enzyme.
    Arimoto R
    Curr Top Med Chem; 2006; 6(15):1609-18. PubMed ID: 16918472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics.
    Forrester LM; Henderson CJ; Glancey MJ; Back DJ; Park BK; Ball SE; Kitteringham NR; McLaren AW; Miles JS; Skett P
    Biochem J; 1992 Jan; 281 ( Pt 2)(Pt 2):359-68. PubMed ID: 1736885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families.
    Lewis DF
    Curr Med Chem; 2003 Oct; 10(19):1955-72. PubMed ID: 12871098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochromes P450 in the bioactivation of chemicals.
    Ioannides C; Lewis DF
    Curr Top Med Chem; 2004; 4(16):1767-88. PubMed ID: 15579107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homology modelling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate selectivity.
    Lewis DF
    Exp Toxicol Pathol; 1999 Jul; 51(4-5):369-74. PubMed ID: 10445400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex-dependent metabolism of xenobiotics.
    Mugford CA; Kedderis GL
    Drug Metab Rev; 1998 Aug; 30(3):441-98. PubMed ID: 9710703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design.
    Rekka EA; Kourounakis PN; Pantelidou M
    Curr Top Med Chem; 2019; 19(4):276-291. PubMed ID: 30706817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.